Sugi Predict

Sugi Predict / Compounds / SCHEMBL9965609

SCHEMBL9965609

SCHEMBL9965609

Oc1c(C(Nc2ccccn2)c2cc(Cl)cc(Cl)c2)ccc2cccnc12

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P4HB P07237 8/20 0.81
▸ TP53 P04637 6/20 0.77
▸ JMJD7 P0C870 1/20 0.77
▸ CYP2D6 P10635 1/20 0.77
▸ CYP2C9 P11712 1/20 0.77
▸ CYP2C19 P33261 1/20 0.77
▸ HIF1A Q16665 1/20 0.77
▸ HSD17B10 Q99714 1/20 0.77
▸ MDM2 Q00987 3/20 0.74
▸ MAPT P10636 5/20 0.71
▸ SMN1; SMN2 Q16637 3/20 0.71
▸ TEAD4 Q15561 1/20 0.71
▸ GRK6 P43250 1/20 0.71
▸ USP2 O75604 2/20 0.69
▸ LMNA P02545 2/20 0.69
▸ KDM4E B2RXH2 1/20 0.69
▸ ALOX15 P16050 1/20 0.69
▸ NFKB1 P19838 1/20 0.69
▸ MAPK1 P28482 1/20 0.69
▸ HTT P42858 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13836221 0.90 P4HB (1.00) P4HBTP53JMJD7CYP2D6CYP2C9
SCHEMBL9965705 0.89 MDM2 (0.79) P4HBTP53JMJD7CYP2D6CYP2C9
SCHEMBL9965574 0.87 MDM2 (0.78) P4HBTP53MDM2MAPTSMN1; SMN2
SCHEMBL9965624 0.87 MAPT (0.86) P4HBTP53JMJD7CYP2D6CYP2C9
SCHEMBL5090192 0.87 TP53 (1.00) P4HBTP53JMJD7CYP2D6CYP2C9
SCHEMBL9965758 0.87 MDM2 (0.79) P4HBTP53JMJD7CYP2D6CYP2C9
SCHEMBL9965766 0.86 MDM2 (0.79) P4HBTP53JMJD7CYP2D6CYP2C9
SCHEMBL21842247 0.86 P4HB (0.77) P4HBTP53JMJD7CYP2D6CYP2C9
SCHEMBL9965733 0.86 MDM2 (0.71) P4HBTP53JMJD7CYP2D6CYP2C9
SCHEMBL9965508 0.85 MDM2 (1.00) P4HBTP53JMJD7CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY JNANA THERAPEUTICS INC. 2021-09-30 — — US disclosed
US-20210300898-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS INC. 2021-09-30 — — US disclosed
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY JNANA THERAPEUTICS INC. 2021-09-30 — — US disclosed
US-20210300898-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS INC. 2021-09-30 — — US disclosed
WO-2020061476-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS, INC. (US) 2020-03-26 — — WO disclosed
US-9273031-B2 Combination therapy with MDM2 and EFGR inhibitors Errico, Joseph P. (US) 2016-03-01 — — US disclosed
US-9238641-B2 — — 2016-01-19 — — US disclosed
US-9073858-B2 Methods of targeted drug development Errico, Joseph P. (US) 2015-07-07 — — US disclosed
US-9023354-B2 Combination therapy with MDM2 and EFGR inhibitors Errico, Joseph P. (US) 2015-05-05 — — US disclosed
US-20150105412-A1 COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS ERRICO, JOSEPH P. 2015-04-16 — — US disclosed
US-20140194439-A1 METHODS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-07-10 — — US disclosed
US-20140163069-A1 COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-06-12 — — US disclosed
US-20140134163-A1 COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS Errico, Joseph P. (US) 2014-05-15 — — US disclosed
US-8658170-B2 Combination therapy with MDM2 and EFGR inhibitors Errico, Joseph P. (US) 2014-02-25 — — US disclosed
US-20120156197-A1 COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS Errico, Joseph P. (US) 2012-06-21 — — US disclosed
US-20110301193-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2011-12-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210300898-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS SNRPE, G3BP1, G3BP2 P4HB 2252/4885TP53 6/4885JMJD7 3726/4885
US-20120156197-A1 COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS TP53, EGFR, MDM2 P4HB 4025/4885TP53 1/4885JMJD7 2561/4885
US-20110301193-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB3 P4HB 2320/4885TP53 230/4885JMJD7 307/4885
US-20140163069-A1 COMPOSITIONS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB3 P4HB 2500/4885TP53 95/4885JMJD7 475/4885
US-20150105412-A1 COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS TP53, EGFR, MDM2 P4HB 4025/4885TP53 1/4885JMJD7 2561/4885
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY SLC19A1, SLC1A5, SLC1A2 P4HB 2832/4885TP53 4180/4885JMJD7 3640/4885
US-20140134163-A1 COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS TP53, EGFR, MDM2 P4HB 4025/4885TP53 1/4885JMJD7 2561/4885
US-20140194439-A1 METHODS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB4 P4HB 2095/4885TP53 192/4885JMJD7 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.